{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:59:34Z","timestamp":1790161174268,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03744-8","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:59:29Z","timestamp":1790157569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease"],"prefix":"10.1007","author":[{"given":"James","family":"Amamoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasvi","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"6","key":"3744_CR1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602\u201310.","journal-title":"JAMA"},{"key":"3744_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12226984","author":"S Swamy","year":"2023","unstructured":"Swamy S, Noor SM, Mathew RO. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12226984.","journal-title":"J Clin Med"},{"issue":"8","key":"3744_CR3","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.37765\/ajmc.2022.89152","volume":"28","author":"NN Iyer","year":"2022","unstructured":"Iyer NN, Li Q, Shah S, Ganz ML, Dang-Tan T, Gamble C, et al. Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022;28(8):e301\u20137.","journal-title":"Am J Manag Care"},{"issue":"5s","key":"3744_CR4","first-page":"S1","volume":"102","author":"KDIGO","year":"2022","unstructured":"KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5s):S1-s127.","journal-title":"Kidney Int"},{"issue":"12","key":"3744_CR5","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"3744_CR6","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association (ADA)","year":"2025","unstructured":"American Diabetes Association (ADA). 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S181-s206.","journal-title":"Diabetes Care"},{"key":"3744_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189800","author":"J Klen","year":"2021","unstructured":"Klen J, Dol\u017ean V. Treatment response to SGLT2 inhibitors: from clinical characteristics to genetic variations. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22189800.","journal-title":"Int J Mol Sci"},{"key":"3744_CR8","doi-asserted-by":"publisher","first-page":"100184","DOI":"10.1016\/j.deman.2023.100184","volume":"13","author":"AJ Scheen","year":"2024","unstructured":"Scheen AJ. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manag. 2024;13:100184.","journal-title":"Diabetes Epidemiol Manag"},{"issue":"1","key":"3744_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02191-2","volume":"20","author":"C Kovesdy","year":"2022","unstructured":"Kovesdy C, Schmedt N, Folkerts K, Bowrin K, Raad H, Batech M, et al. Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors. BMC Med. 2022;20(1):2.","journal-title":"BMC Med"},{"issue":"12","key":"3744_CR10","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/dom.15241","volume":"25","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Shah BR, Zongo A, Eurich DT, Alsabbagh MW, Gamble JM. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: a comparative cohort study from the United Kingdom. Diabetes Obes Metab. 2023;25(12):3490\u2013500.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"3744_CR11","doi-asserted-by":"publisher","first-page":"sfae169","DOI":"10.1093\/ckj\/sfae169","volume":"17","author":"P Perrin","year":"2024","unstructured":"Perrin P, Muller C, Dimitrov Y, Chantrel F, Heitz M, Woerly A, et al. Assessment of SGLT2 inhibitors\u2019 safety and discontinuation causes in patients with advanced chronic kidney disease: insights from a real-world data analysis. Clin Kidney J. 2024;17(7):sfae169.","journal-title":"Clin Kidney J"},{"key":"3744_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12226993","author":"Y Saijo","year":"2023","unstructured":"Saijo Y, Okada H, Hata S, Nakajima H, Kitagawa N, Okamura T, et al. Reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: the KAMOGAWA-A study. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12226993.","journal-title":"J Clin Med"},{"issue":"2","key":"3744_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pcd.2020.10.002","volume":"15","author":"A Tumminia","year":"2021","unstructured":"Tumminia A, Graziano M, Vinciguerra F, Lomonaco A, Frittita L. Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: a real-world experience. Prim Care Diabetes. 2021;15(2):283\u20138.","journal-title":"Prim Care Diabetes"},{"issue":"10","key":"3744_CR14","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324\u20138.","journal-title":"Diabetes"},{"issue":"10","key":"3744_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3744_CR16","doi-asserted-by":"publisher","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"3744_CR17","doi-asserted-by":"publisher","first-page":"108529","DOI":"10.1016\/j.jdiacomp.2023.108529","volume":"37","author":"D Patoulias","year":"2023","unstructured":"Patoulias D, Popovic DS, Stoian AP, Janez A, Sahebkar A, Rizzo M. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. J Diabetes Complicat. 2023;37(8):108529.","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"3744_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"3744_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"6","key":"3744_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","volume":"31","author":"WP Glasheen","year":"2017","unstructured":"Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI)-update and ICD-10 translation. J Diabetes Complicat. 2017;31(6):1007\u201313.","journal-title":"J Diabetes Complicat"},{"issue":"8","key":"3744_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/ckj\/sfac096","volume":"15","author":"B Aviles Bueno","year":"2022","unstructured":"Aviles Bueno B, Soler MJ, Perez-Belmonte L, Jimenez Millan A, Rivas Ruiz F, Garcia de Lucas MD. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clin Kidney J. 2022;15(8):1593\u2013600.","journal-title":"Clin Kidney J"},{"key":"3744_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1240279","volume":"14","author":"MD Garc\u00eda de Lucas","year":"2023","unstructured":"Garc\u00eda de Lucas MD, Caballero I, Fern\u00e1ndez-Garc\u00eda JC, Dom\u00ednguez-Rodr\u00edguez M, Moreno-Moreno P, Jim\u00e9nez-Mill\u00e1n A, et al. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study. Front Endocrinol (Lausanne). 2023;14:1240279.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3744_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ndt\/gfae150","volume":"40","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Cherney DZI, Kuhlman AB, Mann JFE, Rasmussen S, Rossing P, et al. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrol Dial Transplant. 2024;40(2):352\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3744_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","volume":"83","author":"W Wu","year":"2024","unstructured":"Wu W, Tong H-m, Li Y-s, Cui J. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine. 2024;83(3):571\u201384.","journal-title":"Endocrine"},{"issue":"11","key":"3744_CR25","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care. 2020;43(11):2859\u201369.","journal-title":"Diabetes Care"},{"issue":"2","key":"3744_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.kint.2021.10.033","volume":"101","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu EL, Clase CM, Mazhar F, Jardine MJ, Carrero JJ. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. Kidney Int. 2022;101(2):360\u20138.","journal-title":"Kidney Int"},{"issue":"2","key":"3744_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfy407","volume":"34","author":"P Sarafidis","year":"2019","unstructured":"Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. a consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3744_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ekir.2024.11.1365","volume":"10","author":"SS Kotwal","year":"2025","unstructured":"Kotwal SS, Perkovic V. Effects of semaglutide on CKD in patients with type 2 diabetes. Kidney Int Rep. 2025;10(2):287\u201390.","journal-title":"Kidney Int Rep"},{"issue":"17","key":"3744_CR29","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol. 2024;84(17):1615\u201328.","journal-title":"J Am Coll Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03744-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:59:30Z","timestamp":1790157570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03744-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"James Amamoo, Lin Xie, Sherif Mehanna, Josh Noone, and Caroline Swift are employees of Novo Nordisk Inc at the time of the project. Yan Wang, Hongjiao Liu, Manasvi Sundar, and Yan Song are employees of Analysis Group at the time of the project, which has received research funding from Novo Nordisk Inc. Matthew R. Weir is a scientific advisor to Novo Nordisk Inc, AstraZeneca, Bayer, Corcept, CSL Vifor, Mineralys, and Vera.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}